Enveda secures $311M to bring more nature-derived AI drugs into clinical trials

TechCrunchSeptember 23, 2026 at 7:31 PM

The round valued the AI biotech at $2 billion. It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.

This is a summary. For the full story, read the original article at TechCrunch.

Original source: TechCrunch

tech

Related Articles

Scientists Detect Radio Signals from an Exoplanet for the First Time in History

The Best Linux Laptops (2026): System76, Framework, and More

Venus May Have Devoured Its Moon